EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Company limited by guarantee

Company Registration Number:
10585826 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2023

Period of accounts

Start date: 1 April 2022

End date: 31 March 2023

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Contents of the Financial Statements

for the Period Ended 31 March 2023

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Directors' report period ended 31 March 2023

The directors present their report with the financial statements of the company for the period ended 31 March 2023

Principal activities of the company

The company's principal activity during the year was the operation of a worldwide external quality assessment scheme for immunocytochemistry for laboratories.

Additional information

The objects of the company are to carry on activities that benefit the community and in particular (without limitation):To provide an administrative framework supporting the activities of External Quality Assessment (EQA) in cancer diagnostic testing in clinical laboratory sciences. It will operate on a not-for-profit basis; conform to high professional standards; act impartially; be strictly financially accountable. In order that all concerned with the quality of laboratory investigations may have confidence in the services provided, it will assess the quality of clinical laboratory testing in the areas of cancer diagnosis and prediction of treatment response. This testing is carried out in laboratories throughout the UK and worldwide, and by providing external quality assessments, the company will assist healthcare professionals to assure the quality of the work undertaken in their laboratories, which in turn will help to facilitate optimal care for cancer patients undergoing treatment for their disease in the UK and across the world.



Directors

The directors shown below have held office during the whole of the period from
1 April 2022 to 31 March 2023

A R Dodson
S C Parry
L B Whitby
M A Cummins


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
31 December 2023

And signed on behalf of the board by:
Name: A R Dodson
Status: Director

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Profit And Loss Account

for the Period Ended 31 March 2023

2023 2022


£

£
Turnover: 1,690,244 1,292,548
Cost of sales: ( 249,545 ) ( 193,402 )
Gross profit(or loss): 1,440,699 1,099,146
Administrative expenses: ( 1,220,995 ) ( 993,509 )
Other operating income: 188
Operating profit(or loss): 219,704 105,825
Interest receivable and similar income: 1
Interest payable and similar charges: ( 126 )
Profit(or loss) before tax: 219,578 105,826
Tax: ( 29,673 ) ( 43,914 )
Profit(or loss) for the financial year: 189,905 61,912

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Balance sheet

As at 31 March 2023

Notes 2023 2022


£

£
Fixed assets
Intangible assets: 3 150,901 161,509
Tangible assets: 4 492,344 325,564
Total fixed assets: 643,245 487,073
Current assets
Stocks: 5 19,814 18,013
Debtors: 6 495,281 747,410
Cash at bank and in hand: 606,051 537,951
Total current assets: 1,121,146 1,303,374
Creditors: amounts falling due within one year: 7 ( 561,636 ) ( 817,284 )
Net current assets (liabilities): 559,510 486,090
Total assets less current liabilities: 1,202,755 973,163
Provision for liabilities: ( 122,217 ) ( 92,544 )
Total net assets (liabilities): 1,080,538 880,619
Members' funds
Profit and loss account: 1,080,538 880,619
Total members' funds: 1,080,538 880,619

The notes form part of these financial statements

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Balance sheet statements

For the year ending 31 March 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 31 December 2023
and signed on behalf of the board by:

Name: A R Dodson
Status: Director

The notes form part of these financial statements

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

    Tangible fixed assets depreciation policy

    Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life.

    Intangible fixed assets amortisation policy

    Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses. Amortisation is provided on all intangible fixed assets.

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

  • 2. Employees

    2023 2022
    Average number of employees during the period 10 9

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

3. Intangible assets

Goodwill Other Total
Cost £ £ £
At 1 April 2022 228,852 228,852
Additions 39,693 39,693
Disposals
Revaluations
Transfers
At 31 March 2023 268,545 268,545
Amortisation
At 1 April 2022 67,343 67,343
Charge for year 50,301 50,301
On disposals
Other adjustments
At 31 March 2023 117,644 117,644
Net book value
At 31 March 2023 150,901 150,901
At 31 March 2022 161,509 161,509

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

4. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 April 2022 308,542 262,876 571,418
Additions 832 334,938 335,770
Disposals ( 75,550 ) ( 75,550 )
Revaluations
Transfers
At 31 March 2023 309,374 522,264 831,638
Depreciation
At 1 April 2022 95,636 150,218 245,854
Charge for year 42,748 107,118 149,866
On disposals ( 56,426 ) ( 56,426 )
Other adjustments
At 31 March 2023 138,384 200,910 339,294
Net book value
At 31 March 2023 170,990 321,354 492,344
At 31 March 2022 212,906 112,658 325,564

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

5. Stocks

2023 2022
£ £
Stocks 19,814 18,013
Total 19,814 18,013

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

6. Debtors

2023 2022
£ £
Trade debtors 390,770 650,170
Prepayments and accrued income 69,476 59,005
Other debtors 35,035 38,235
Total 495,281 747,410

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Notes to the Financial Statements

for the Period Ended 31 March 2023

7. Creditors: amounts falling due within one year note

2023 2022
£ £
Trade creditors 53,490 56,206
Taxation and social security 23,261 98,411
Accruals and deferred income 458,136 654,037
Other creditors 26,749 8,630
Total 561,636 817,284

COMMUNITY INTEREST ANNUAL REPORT

EXTERNAL QUALITY ASSESSMENT SERVICES FOR CANCER DIAGNOSTICS C.I.C.

Company Number: 10585826 (England and Wales)

Year Ending: 31 March 2023

Company activities and impact

The Company has supported the activities of a UK-based external quality assessment (EQA) scheme, which provides its services to healthcare laboratories throughout the world.Currently the number of laboratories receiving EQA services is in excess of 500, with approximately 40% of them being based in the UK.By providing these EQA services the Company through its Scheme allows laboratories to benchmark the quality of their clinical testing activities against those of its peers, providing assurance that the quality of testing is good in the vast majority of cases. Where deficiencies in test quality are identified the Scheme works with the laboratory to improve that quality, through the provision of education and advice.

Consultation with stakeholders

There has been consultation with all stakeholder groups.1.Clinical laboratories participating in the EQA activities are provided with an annual questionnaire designed to obtain their feedback about all aspects of the EQA services. The company provides an outward-facing website, through which participants may contact the EQA Scheme.2.The EQA Scheme is part of a wider consortium of similar operations hosted by various legal entities (mainly NHS teaching hospitals). Directors from EQASCD CIC regularly attend joint meetings of that consortium group (up to 7 meetings per year).

Directors' remuneration

The total amount paid or receivable by directors in respect of qualifying services was £266,793.There were no other transactions or arrangements in connection with the remuneration of directors which require to be disclosed.

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
29 December 2023

And signed on behalf of the board by:
Name: A R Dodson
Status: Director